Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema

被引:16
|
作者
Mushtaq, Bushra [1 ]
Crosby, Niall J. [1 ]
Dimopoulos, Antonios T. [1 ]
Lip, Peck Lin [1 ]
Stavrou, Panagiota [1 ]
El-Sherbiny, Samer [1 ]
Yang, Yit [2 ]
机构
[1] City & Sandwell Natl Hlth Serv Trust, Birmingham & Midland Eye Ctr, Dudley Rd, Birmingham B18 7QH, W Midlands, England
[2] Aston Univ, Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England
来源
CLINICAL OPHTHALMOLOGY | 2014年 / 8卷
关键词
anti-VEGF therapy; central retinal thickness; ranibizumab; intravitreal injection; optical coherence tomography;
D O I
10.2147/OPTH.S56624
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT).400 mu m had better visual and anatomical outcomes compared to eyes with a CRT,400 mu m when treated with intravitreal bevacizumab in a real-world setting. Patients and methods: Patients undergoing intravitreal bevacizumab therapy for DME were identified from the departmental database of a tertiary referral unit. Following the initial injection, a retreatment was performed for any persistent macular edema, unless there had been no previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT characteristics. Comparisons were made between data at baseline and 12 months after the first injection, and differences were tested for statistical significance using the Student's t-test. Results: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT.400 mu m) had significantly more injections than group 1 (CRT<400 mu m) (4.0 versus 3.3; P=0.003). Both groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular traction at baseline. The reduction in CRT was significantly greater in group 2 when compared to group 1 (P<0.0001). In terms of visual gain between baseline and month 12, each gained significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), but there was no difference between groups 1 and 2 (P=0.99). Conclusion: These results do not support a 400 mu m baseline CRT cut-off for treating DME with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that patients with a thicker CRT require more bevacizumab injections, making treatment less costeffective for these patients. Our results could be used by practitioners to support the use of bevacizumab in DME without applying a CRT cut-off.
引用
收藏
页码:807 / 812
页数:6
相关论文
共 50 条
  • [1] Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema
    Chung, Eun Jee
    Roh, Mi In
    Kwon, Oh Woong
    Koh, Hyoung Jun
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2008, 28 (07): : 957 - 963
  • [2] Effect of intravitreal bevacizumab in diabetic macular edema
    Shaikh, Fahad Feroze
    Arain, Aziz-ur-Rehman
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2011, 27 (03) : 651 - 655
  • [3] Effect of Intravitreal Triamcinolone Acetonide or Bevacizumab on Choroidal Thickness in Eyes With Diabetic Macular Edema
    Sonoda, Shozo
    Sakamoto, Taiji
    Yamashita, Takehiro
    Otsuka, Hiroki
    Shirasawa, Makoto
    Kakiuchi, Naoko
    Uchino, Eisuke
    Terasaki, Hiroto
    Kawano, Hiroki
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (06) : 3979 - 3985
  • [4] EFFECT OF INTRAVITREAL TRIAMCINOLONE IN DIABETIC MACULAR EDEMA UNRESPONSIVE TO INTRAVITREAL BEVACIZUMAB
    Jeon, Sohee
    Lee, Won Ki
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (08): : 1606 - 1611
  • [5] Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular Edema
    Nazmiye Erol
    Huseyin Gursoy
    Sabit Kimyon
    Seyhan Topbas
    Ertugrul Colak
    [J]. Advances in Therapy, 2012, 29 : 359 - 369
  • [6] Vision, Retinal Thickness, and Foveal Avascular Zone Size After Intravitreal Bevacizumab for Diabetic Macular Edema
    Erol, Nazmiye
    Gursoy, Huseyin
    Kimyon, Sabit
    Topbas, Seyhan
    Colak, Ertugrul
    [J]. ADVANCES IN THERAPY, 2012, 29 (04) : 359 - 369
  • [7] Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates
    Jeon, Sohee
    Lee, Won Ki
    [J]. CLINICAL OPHTHALMOLOGY, 2014, 8 : 1479 - 1486
  • [8] Intravitreal injection of Bevacizumab in diabetic macular edema
    Ateeq, Asim
    Tahir, Muhammad Ali
    Cheema, Alyscia
    Dahri, Arif
    Tareen, Saifullah
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2014, 30 (06) : 1383 - 1387
  • [9] Intravitreal Bevacizumab in the Treatment of Diabetic Macular Edema
    Salvetti, P. A.
    Bonavia, L.
    Rosina, C.
    Sabella, P.
    Draghi, M.
    Staurenghi, G.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [10] Intravitreal bevacizumab (Avastin) for diabetic macular edema
    Pognuz, D. R.
    Menchini, F.
    Bandello, F.
    [J]. EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (03) : 474 - 475